The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: ALK Inhibitor in Metastatic Colorectal Cancer With ALK Mutation.
Official Title: ALK Inhibitor in Metastatic Colorectal Cancer With ALK Mutation.
Study ID: NCT03792568
Brief Summary: This clinical trial aims to evaluate the efficacy, safety of ALK inhibitor in Metastatic Colorectal Cancer Patients with ALK mutation.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
Shanghai Changzheng Hospital, Shanghai, Shanghai, China